The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

Jun 16, 2020
Share:

During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, AU, about the phase I study of CD20-TCB (glofitamab) in relapsed/refractory non-Hodgkin lymphoma.

CD20-TCB is a novel T-cell-engaging bispecific antibody that has demonstrated high potency in the presence of other anti-CD20 antibodies. A phase I dose-escalation study (NCT03075696), evaluating the efficacy, safety, tolerability, and pharmacokinetic profile of CD20-TCB, is currently underway. Here, Michael Dickinson outlines the high response and complete remission rates observed amongst patients receiving active doses of CD20-TCB.

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

Share: